However, STI-6643 treatment re-established a more physiological CD4:CD8 ratio of 2:1 and remained functional as indicated by their ability to induce GVHD with the same kinetics as the isotype control-treated mice (Figure 8B). This evidence concerns the gene CD8A and graft versus host disease.